TD Cowen analyst Brendan Smith lowered the firm’s price target on Twist Bioscience (TWST) to $36 from $58 and keeps a Buy rating on the shares. The stock has been under pressure following Q3 revenue that was in line with guidance and the narrowing of FY25 guidance as investor hoped for “a clean beat/raise.” The firm, which is trimming near-term estimstes for SynBio, largely offset by consistent NGS growth into next year, now assigns a multiple closer to peer trading multiples to reflect updated growth assumptions.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- Twist Bioscience’s Growth Driven by NGS Success and Resilience: Buy Rating Affirmed
- Twist Bioscience price target lowered to $46 from $50 at Evercore ISI
- Tesla grants Musk big payout, Wayfair reports Q2 beat: Morning Buzz
- Twist Bioscience falls -16.4%
- Morning Movers: Wayfair surges following second quarter results